Rekah Pharmaceutical Industry Ltd.

Tel Aviv Stock Exchange REKA.TA

Rekah Pharmaceutical Industry Ltd. Price to Book Ratio (P/B) on January 14, 2025: 1.00

Rekah Pharmaceutical Industry Ltd. Price to Book Ratio (P/B) is 1.00 on January 14, 2025, a 14.22% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Rekah Pharmaceutical Industry Ltd. 52-week high Price to Book Ratio (P/B) is 3.62 on December 20, 2024, which is 261.23% above the current Price to Book Ratio (P/B).
Rekah Pharmaceutical Industry Ltd. 52-week low Price to Book Ratio (P/B) is 0.72 on June 10, 2024, which is -27.80% below the current Price to Book Ratio (P/B).
Rekah Pharmaceutical Industry Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 0.90.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Tel Aviv Stock Exchange: REKA.TA

Rekah Pharmaceutical Industry Ltd.

CEO	Mr. Mordechai Elgrabli
IPO Date	Aug. 12, 2002
Location	Israel
Headquarters	30 Hamelach Street
Employees	427
Sector	Health Care
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies

Description

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.

Key trends

Past 5 years